Author
Listed:
- Guillermo N. Armaiz-Pena
(The University of Texas MD Anderson Cancer Center)
- Julie K. Allen
(The University of Texas MD Anderson Cancer Center
Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center)
- Anthony Cruz
(University of Puerto Rico)
- Rebecca L. Stone
(The University of Texas MD Anderson Cancer Center)
- Alpa M. Nick
(The University of Texas MD Anderson Cancer Center)
- Yvonne G. Lin
(The University of Texas MD Anderson Cancer Center)
- Liz Y. Han
(The University of Texas MD Anderson Cancer Center)
- Lingegowda S. Mangala
(The University of Texas MD Anderson Cancer Center
Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center)
- Gabriel J. Villares
(Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center
The University of Texas MD Anderson Cancer Center)
- Pablo Vivas-Mejia
(The University of Texas MD Anderson Cancer Center
Medical Sciences Campus, University of Puerto Rico)
- Cristian Rodriguez-Aguayo
(The University of Texas MD Anderson Cancer Center)
- Archana S. Nagaraja
(The University of Texas MD Anderson Cancer Center
Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center)
- Kshipra M. Gharpure
(The University of Texas MD Anderson Cancer Center
Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center)
- Zheng Wu
(Biomolecular Resource Facility, The University of Texas Medical Branch
The University of Texas Medical Branch)
- Robert D. English
(Biomolecular Resource Facility, The University of Texas Medical Branch)
- Kizhake V. Soman
(Biomolecular Resource Facility, The University of Texas Medical Branch
The University of Texas Medical Branch)
- Mian M. K. Shahzad
(The University of Texas MD Anderson Cancer Center)
- Maya Zigler
(Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center
The University of Texas MD Anderson Cancer Center)
- Michael T. Deavers
(The University of Texas MD Anderson Cancer Center)
- Alexander Zien
(Molecular Health GmbH)
- Theodoros G. Soldatos
(Molecular Health GmbH)
- David B. Jackson
(Molecular Health GmbH)
- John E. Wiktorowicz
(Biomolecular Resource Facility, The University of Texas Medical Branch
The University of Texas Medical Branch)
- Madeline Torres-Lugo
(University of Puerto Rico)
- Tom Young
(Lehman College)
- Koen De Geest
(University of Iowa)
- Gary E. Gallick
(The University of Texas MD Anderson Cancer Center)
- Menashe Bar-Eli
(The University of Texas MD Anderson Cancer Center)
- Gabriel Lopez-Berestein
(Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center)
- Steve W. Cole
(University of California)
- Gustavo E. Lopez
(University of Puerto Rico)
- Susan K. Lutgendorf
(University of Iowa
and Holden Comprehensive Cancer Center, University of Iowa)
- Anil K. Sood
(The University of Texas MD Anderson Cancer Center
Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center)
Abstract
Noradrenaline can modulate multiple cellular functions important for cancer progression; however, how this single extracellular signal regulates such a broad array of cellular processes is unknown. Here we identify Src as a key regulator of phosphoproteomic signalling networks activated in response to beta-adrenergic signalling in cancer cells. These results also identify a new mechanism of Src phosphorylation that mediates beta-adrenergic/PKA regulation of downstream networks, thereby enhancing tumour cell migration, invasion and growth. In human ovarian cancer samples, high tumoural noradrenaline levels were correlated with high pSrcY419 levels. Moreover, among cancer patients, the use of beta blockers was significantly associated with reduced cancer-related mortality. Collectively, these data provide a pivotal molecular target for disrupting neural signalling in the tumour microenvironment.
Suggested Citation
Guillermo N. Armaiz-Pena & Julie K. Allen & Anthony Cruz & Rebecca L. Stone & Alpa M. Nick & Yvonne G. Lin & Liz Y. Han & Lingegowda S. Mangala & Gabriel J. Villares & Pablo Vivas-Mejia & Cristian Rod, 2013.
"Src activation by β-adrenoreceptors is a key switch for tumour metastasis,"
Nature Communications, Nature, vol. 4(1), pages 1-12, June.
Handle:
RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms2413
DOI: 10.1038/ncomms2413
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms2413. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.